Pharma News
07 Sep 2025 to 13 Sep 2025
Sep 13, 2025
Korea plans to increase its biopharmaceutical exports twofold by 2030 and create three major new medications.
South Korea aims to double biopharma exports by 2030 and develop three blockbuster drugs, as announced during the Bio Innovation Roundtable in Incheon. The government plans to cut biosimilar approval review periods from 406 to 295 days and enhance regulations to support rapid medicine release, focusing on AI-driven drug discovery and training 110,000 specialists.
Sep 13, 2025
Doctors express concern over Ozempic-like medications: 'The advantages are completely diminished'
A study reveals that over half of first-time users of semaglutide-based GLP-1 drugs, like Ozempic and Wegovy, discontinue treatment within a year, often due to high costs and side effects. Younger users and those in low-income areas are particularly affected. Understanding these drop-off rates is crucial for improving long-term treatment adherence and health outcomes.
Sep 13, 2025
Navigating the Challenges and Benefits of Intellectual Property in the Biopharmaceutical Industry: A Focus on Patents...
The biopharmaceutical industry faces challenges balancing innovation and patent protection, with companies like Sanofi developing amlitelimab to extend market dominance amid patent cliffs. A $5 billion licensing deal for RNA drug technologies highlights strategic moves to mitigate IP risks. As litigation costs rise, firms are shifting towards collaborative resolutions, emphasizing the need for resilience in navigating patent landscapes.
Sep 13, 2025
AbbVie Resolves Patent Conflict Over Rinvoq: Implications for Stock Performance - sharewise
AbbVie (ABBV) shares surged over 4% to a record high after settling patent litigation with generic manufacturers for its immunology drug, Rinvoq (upadacitinib). The settlement extends exclusivity until April 2037, boosting sales, which rose 48% to nearly $3.75 billion in H1 2025. AbbVie anticipates combined sales from Rinvoq and Skyrizi to exceed $25 billion in 2025.
Sep 13, 2025
AbbVie Experiences 0.85% Decline Following $970 Million Decrease in Volume, Falling to 79th Position as a Leading Biopharma Company...
AbbVie is navigating investor caution amid market changes, focusing on its portfolio of blockbuster drugs and innovation to drive long-term growth. Analysts are watching for regulatory updates and R&D milestones that could impact sentiment. The company's capital allocation strategies, including dividends and share repurchases, remain crucial for investor confidence despite economic challenges.
Sep 13, 2025
Indian pharmaceutical companies are strategically pivoting to develop innovative generics through the 505(b)(2) pathway to establish a presence in the global market.
Indian pharma companies are shifting from me-too drugs to differentiated generics using the US FDA’s 505(b)(2) pathway, according to Dr. Hemagir Gosavi of Merck Life Sciences. The Merck Formulation and Technology Centre supports this innovation with excipients, enhancing drug stability and compliance. This collaboration aims to improve marketability and regulatory compliance for Indian generics in global markets.
Sep 13, 2025
Police and Brand Protection team take significant measures in Gaya, seizing counterfeit medications valued at lakhs.
In a significant operation in Gaya, the Brand Protection team, alongside local police, seized counterfeit medicines valued at lakhs. The raid targeted fake products including BioOil from Geneva Laboratories, Omnigel Spray from Cipla Health, Acnemoist Cream from Torrent Pharma, and Neem Face Wash from Himalaya Wellness.
Sep 12, 2025
US Market Report on Generic Injectables for 2025-2033 | Important Insights - GlobeNewswire
The US generic injectables market, valued at USD 21.8 billion in 2024, is projected to grow to USD 47.6 billion by 2033, driven by rising demand for cost-effective healthcare and patent expirations. Key players like Hospira (Pfizer Inc.), Hikma Pharmaceuticals, and Sandoz are expanding their portfolios and manufacturing capabilities to meet this demand.
Sep 12, 2025
Could the Exercise of March-in Rights Reduce Prices for Biologics? | Goodwin - JDSupra
The Bayh-Dole Act allows the federal government to retain rights in federally funded inventions, but it has never exercised its "march-in" rights to lower drug prices. Despite calls for action, the Department of Health and Human Services recently denied a petition regarding Xtandi® (enzalutamide), citing its market availability. Notably, many expensive biologics, including Avastin and Eylea, lack the required government support statement.
Sep 12, 2025
Authorities in Fatehabad confiscate narcotic pills and capsules valued at lakhs of rupees; a young man from Sirsa taken into custody.
Fatehabad police seized 13,800 narcotic pills and capsules valued at lakhs of rupees. A youth from Sirsa was arrested in connection with the case, which has been registered under relevant drug laws.
Sep 12, 2025
Generic and biosimilar markets face challenges even after achieving $467 billion in savings for 2024 | TechTarget
In 2024, generic and biosimilar medicines in the U.S. saved $467 billion, totaling $3.4 trillion over the past decade, according to the Association for Accessible Medicines. However, challenges like falling prices, PBM practices, and a lack of biosimilar development threaten market stability. Biosimilars, including Humira alternatives, show mixed adoption rates, with significant gaps in the development pipeline.
Sep 12, 2025
AbbVie Attains Rinvoq Exclusivity Through 2037, Reports 53% Sales Increase - AInvest
AbbVie has reached a settlement and licensing agreement with generic drug manufacturers regarding Rinvoq, its key immunology drug, ensuring that generic versions will not enter the U.S. market until April 2037. This move protects AbbVie's market share and revenue, especially as Rinvoq's sales surged 53% in the first half of 2025, positioning it as a successor to Humira.
Sep 12, 2025
Dispute Regarding Clinical Data of Popular Medication Leads to Significant Decline in Stock Value for ...
Kangfang Biotech has reported promising clinical data for its lung cancer drug, Ewoxi, particularly from the HARMONi study, indicating improved overall and progression-free survival rates. Despite this, Kangfang's stock has fallen by 21% since August, partly due to concerns over the drug's overseas approval prospects and competition with Keytruda. The market remains cautious amid uncertainties surrounding Ewoxi's efficacy and pricing.
Sep 12, 2025
LB Pharmaceuticals Secures $285 Million in First Significant Biotech IPO Since February - AInvest
LB Pharmaceuticals raised $285 million in its IPO, pricing 19 million shares at $15 each, to advance its schizophrenia drug LB-102. Meanwhile, Argenx SE's Vyvgart (efgartigimod alfa) generated $2.2 billion in 2024, with a projected market size of $5.5 billion by 2030. Argenx is also advancing empasiprubart in late-stage trials for autoimmune conditions.
Sep 12, 2025
Analysts Predict Multi-Billion Dollar Increase as AbbVie's Rinvoq Remains Without Generics Until 2037
AbbVie shares surged 4% to a record high after the company announced no generic competition for its immunology drug Rinvoq until 2037. This extension is expected to bolster sales amid declining revenues from Humira, which faces biosimilar competition. Rinvoq generated $5.97 billion in 2024, contributing over 10% to AbbVie's revenue.
Sep 12, 2025
Authorities dismantle illegal ayurvedic medicine production facility in Valsad, confiscating equipment and raw materials.
Authorities in Valsad, Gujarat, have shut down an illegal Ayurvedic medicine factory located near the Vishwambhari temple. The Food and Drug Administration (FDA) conducted a raid, seizing raw materials and machinery used in the unauthorized production of Ayurvedic products.
Sep 12, 2025
Argenx: A Biotechnology Company Concentrating on R&D - AInvest
Argenx, a Dutch biotech firm, is gaining attention for its therapeutic antibody, Vyvgart (efgartigimod alfa), which generated $2.2 billion in 2024. The company invests heavily in R&D, spending $1.05 billion, but faces risks from trial outcomes and revenue concentration. Despite competition and potential patent issues, Argenx's promising pipeline and growth strategy make it an intriguing investment opportunity.
Sep 12, 2025
The Creator of Ozempic Is Rapidly Laying Off a Large Number of Staff - Futurism
Novo Nordisk is laying off 9,000 employees, about 11% of its workforce, as it faces increased competition in the GLP-1 market from Eli Lilly's Mounjaro and Zepbound. The company aims to save $1.3 billion by 2026 amid declining profits and a hiring freeze. CEO Maziar Mike Doustdar acknowledged the need for a strategic shift to remain competitive.
Sep 12, 2025
UT authorities conduct a raid on an unregistered medical device store, confiscating infusion pumps valued at Rs 8 lakh.
The Chandigarh Administration raided an unlicensed medical device shop, seizing 1,050 imported infusion pumps valued at around Rs 8 lakh. The operation was conducted under the direction of the Chief Secretary, highlighting ongoing efforts to regulate medical device sales in the region.
Sep 12, 2025
DCGI grants approval for fixed-dose combination of voglibose 0.2 mg and metformin HCl 500 mg - Drug Regulatory Authority
The Drugs Controller General of India (DCGI) has approved a fixed dose combination (FDC) of voglibose 0.2 mg and metformin HCl 500 mg in sustained release form for antidiabetic treatment. This decision was communicated to state and Union Territory drug controllers on September 12, 2025.
Sep 12, 2025
Telangana DCA conducts a raid on a fraudulent clinic in Nizamabad, according to DrugsControl Media Services.
Telangana Drug Control Administration (DCA) conducted a raid on a quack's clinic in Nizamabad on September 10, seizing a stock of antibiotics and other medicines. The enforcement team acted on credible information to address illegal medical practices in the region.
Sep 12, 2025
Undermining US Drug Innovation: Debunking Myths About Drug Pricing (Part II) | Americas
Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax discuss in a two-part series how changes in legislative, judicial, and executive policies have significantly impacted the risks associated with drug innovation.
Sep 12, 2025
Novo Nordisk vs. Mylan: Treatment Method Claims Need to Correspond with Labeling - Mondaq
In the recent case of Novo Nordisk v. Mylan, the District of Delaware ruled that method-of-treatment claims must align with FDA-approved drug labels. Novo Nordisk's patent for Wegovy® was challenged by Mylan's ANDA for a generic version. The court found Mylan's label did not instruct against coadministration with other drugs, undermining Novo's infringement claims.
Sep 12, 2025
Risks of Patent Disputes in Technology-Focused Biotechnology Companies: The Case of Alpha Modus's Legal Action - AInvest
The lawsuit by Alpha Modus against MNTN Inc. highlights the rising risks of patent litigation in biotech, where AI and synthetic biology are reshaping innovation. As firms face increasing legal battles over intellectual property, investors must assess both scientific merit and legal strategies. The case underscores the financial toll of patent disputes, with the biopharma industry projected to lose up to $350 billion by 2030.
Sep 12, 2025
Dutch cancer treatment advancement hindered by pharmaceutical companies, reports FD - DutchNews.nl
Dutch oncologists at Antoni van Leeuwenhoek hospital have developed innovative immunotherapy treatments that cure advanced bowel cancer patients with fewer drugs. However, the methods face opposition from Bristol Myers Squibb (BMS), the drugmaker holding the license, which has delayed regulatory approval due to financial concerns. Despite this, Dutch doctors have secured national approval to offer the treatment.
Sep 11, 2025
AbbVie Secures Patent Extension for Rinvoq Through 2037 - AInvest
AbbVie has secured extended patent protection for its autoimmune drug Rinvoq until April 2037, resulting in a 4.4% rise in its stock to $220.88. This settlement with generic manufacturers enhances AbbVie's revenue outlook, with analysts projecting peak Rinvoq sales of $19 billion by 2033. The company anticipates combined revenue from Rinvoq and Skyrizi to exceed $31 billion by 2027.
Sep 11, 2025
Storing Unapproved Medications on Clinic Shelves Constitutes an "Offer for Sale," According to Drug Regulatory Authorities
The Himachal Pradesh High Court ruled that stocking unlicensed allopathic medicines in clinics constitutes an "offer for sale," violating section 27 of the Drugs and Cosmetics Act. This decision emphasizes the importance of adhering to licensing regulations in the pharmaceutical industry.
Sep 11, 2025
K-Bio Pharmaceutical Sector Aims to Boost Innovation and Rank Among the World's Top Five Leaders
The South Korean government aims to position its bio-pharmaceutical industry among the global top five by 2030, targeting a doubling of exports and the development of three blockbuster drugs. Key initiatives include reducing approval times for biosimilars and enhancing regulatory reforms. The Bio Innovation Roundtable gathered industry leaders to discuss strategies for achieving these ambitious goals.
Sep 11, 2025
Trump may target our medication costs, and universities should assist us in defending against this.
Canadian pharmaceutical companies face challenges in the global market as U.S. President Trump's Executive Order targets discounted drug prices in Canada, labeling it as "freeloading." The reliance on foreign patents restricts domestic innovation. To strengthen the industry, suggestions include incentivizing universities to collaborate with local firms and utilizing graduate students to enhance partnerships.
Sep 11, 2025
Zai Lab faces scrutiny regarding clinical outcomes and competing medications - Insights for global investors in Chinese stocks.
Zai Lab Ltd. faced a significant drop in shares following disappointing Phase Three trial results for its gastric cancer drug, bemarituzumab, which showed weaker survival benefits than expected. The company's quarterly earnings also missed expectations, with sales declines for core products Vyvgart and Zejula. Zai Lab is shifting towards self-developed R&D, focusing on its candidate ZL-1310 for small-cell lung cancer.
Sep 11, 2025
Novo Nordisk Reveals Significant Job Cuts: 9,000 Positions Eliminated Globally to Achieve Annual Savings of $1.26 Billion
Novo Nordisk announced a major restructuring plan, laying off about 9,000 employees, or 11% of its workforce, to save 8 billion Danish kroner ($1.26 billion) by 2026. The layoffs, primarily in Denmark, aim to streamline operations amid rising competition in the obesity treatment market, particularly from Eli Lilly. The company will incur one-time restructuring costs of 9 billion Danish kroner ($1.41 billion).
Sep 11, 2025
WHO includes popular weight loss medications in its essential medicines list - The Indian Express
The WHO has updated its Model List of Essential Medicines, adding obesity drugs like semaglutide, dulaglutide, liraglutide, and tirzepatide, alongside cancer treatments such as pembrolizumab (Keytruda), atezolizumab, and cemiplimab. This inclusion aims to enhance access to vital medications, particularly in underserved areas, while addressing high costs and promoting generic competition.
Sep 11, 2025
INDUSTRY UPDATE: Trump considers restrictions on Chinese pharmaceuticals, facing opposition from the industry
The Trump administration is considering restrictions on importing drugs and therapies from China, potentially impacting the U.S. pharmaceutical industry. A draft executive order would require reviews by CFIUS and increase FDA scrutiny on Chinese clinical trial data. Companies like Pfizer, AstraZeneca, and Merck, which rely on Chinese drugs, oppose the move amid rising competition from China's biotech sector.
Sep 11, 2025
J Ints Bio introduces a new fourth-generation targeted anti-cancer drug candidate - KED Global
Yuhan Corp.'s lung cancer drug, Lazertinib, marketed as Leclaza in South Korea, is projected to achieve blockbuster status with annual sales exceeding 1 trillion won ($722 million) by 2027.
Sep 11, 2025
Strengthening Leadership and Strategic Shifts: The Transformation of Immix Biopharma ... - AInvest
Immix Biopharma, Inc. has appointed Dr. Nancy T. Chang to its board and secured a significant investment from Goose Capital, enhancing its strategic focus on advanced cell therapies. The company’s lead candidate, NXC-201, has received RMAT and Orphan Drug Designations, positioning it for success in treating AL Amyloidosis. These moves underscore the importance of experienced leadership in biotech innovation and investor confidence.
Sep 11, 2025
Sandoz disputes Bayer's approach to Xarelto in a lawsuit for damages - JUVE Patent
The UK High Court ruled on Bayer's interim injunctions against Sandoz regarding the patent for Xarelto, which contains rivaroxaban. Sandoz seeks higher compensation than the conventional loss of profits, arguing exceptional circumstances. Bayer's patent remains upheld in several countries, despite its invalidation in the UK. The case could influence similar disputes across Europe.
Sep 11, 2025
Legacy Portfolio Encounters Common Issues as Opdivo and Reblozyl Sales Increase
Bristol Myers Squibb (BMY) shares have dropped 19.2% over six months, underperforming the market. Despite challenges with legacy drugs, BMY's growth portfolio, including Opdivo and Reblozyl, showed an 18% revenue increase in Q2 2025. Analysts predict a potential turnaround, although risks remain. The company's focus on innovation and strategic partnerships may help mitigate these challenges.
Sep 10, 2025
AHF Protests Gilead's Price Increases Impacting ADAP Programs and HIV Patients
Advocates from the AIDS Healthcare Foundation (AHF) will protest at Gilead Sciences' headquarters on September 10, 2025, against recent price hikes on key HIV medications, including Descovy. The protest highlights Gilead's corporate practices, including limiting access to discount programs and manipulating patents, which have significantly impacted HIV patients and assistance programs.
Sep 10, 2025
WHO Supports Use of Weight-Loss Medications for Diabetes and Obesity Treatment, Calls for Affordable Generic Options - NDTV
The WHO has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for diabetes and obesity. The agency urges the production of affordable generics to ensure access in developing countries, where obesity-related deaths are high. The patent for semaglutide will expire soon, potentially lowering costs significantly.
Sep 10, 2025
WHO supports weight-loss medications and calls for affordable generic options.
The World Health Organization has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for treating diabetes and obesity. The WHO urges the production of affordable generic versions to ensure access in developing countries, where obesity-related deaths are significant. The patent for semaglutide is set to expire soon, potentially lowering costs.
Sep 10, 2025
'Upcoming Weight Loss Medication: A New Drug Promises 30% Weight Reduction' - The Times of India
Scientists at Tufts University are creating an experimental drug that targets four hormones—GLP-1, GIP, glucagon, and PYY—to promote significant weight loss with fewer side effects than existing GLP-1 medications. This novel approach seeks to replicate the effects of bariatric surgery, potentially providing a safer and more effective obesity treatment.
Sep 10, 2025
WHO includes important weight-loss medications in its essential medicines list - The Times of India
The WHO has added weight-loss drugs Semaglutide (Wegovy) and Tirzepatide (Mounjaro) to its Model List of Essential Medicines, potentially lowering their prices in India. Currently, Wegovy costs Rs 17,000-26,000 and Mounjaro Rs 14,000-27,000 monthly. The WHO emphasizes the need for increased access to these medications to combat rising obesity and diabetes rates globally.
Sep 10, 2025
Novo Nordisk cuts 9,000 positions to streamline operations amid intense competition in the weight-loss medication market.
Novo Nordisk plans to cut 9,000 jobs, marking Denmark's largest layoffs, to revive growth after declining sales of its weight-loss drug Wegovy. The restructuring aims to save $1.25 billion annually amid competition from Eli Lilly's Zepbound. The company will reinvest savings into its drug pipeline and obesity market expansion, as it faces challenges in maintaining market share.
Sep 10, 2025
Major Legislation Limits Medications Subject to Price Negotiations
The One Big Beautiful Bill delays Medicare price negotiations for orphan drugs, potentially impacting cost control. Notable drugs like Merck's Keytruda and Bristol Myers Squibb's Opdivo, both oncology blockbusters, are exempted or face delayed negotiations. Analysts warn this could inflate Medicare spending, with beneficiaries facing higher co-payments and rising insurance premiums.
Sep 10, 2025
Cost-effectiveness of GLP-1 medications shows improvement, according to five reports - Becker's Hospital Review
A new analysis by the Institute for Clinical and Economic Review reveals that GLP-1 drugs, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Zepbound and Mounjaro, are cost-effective for obesity treatment, offering significant health benefits. Despite their effectiveness, high prices pose affordability challenges, impacting insurance costs and coverage decisions.
Sep 10, 2025
J&J Receives FDA Authorization for Inlexzoh, Boosting Pipeline Progress
Johnson & Johnson (JNJ) has received FDA approval for TAR-200, branded as Inlexzoh, a novel treatment for high-risk non-muscle invasive bladder cancer. This drug-releasing system targets patients unresponsive to Bacillus Calmette-Guérin therapy. J&J anticipates launching Inlexzoh later this year, bolstering its oncology portfolio alongside other drugs like Imaavy and Caplyta, which are also showing strong sales growth.
Sep 10, 2025
Novo Nordisk, the company behind Wegovy and Ozempic, plans to reduce its workforce by 9,000 positions.
Danish pharmaceutical company Novo Nordisk, known for its weight-loss drug Wegovy and diabetes medication Ozempic, announced it will cut 9,000 jobs, 11% of its workforce, to streamline operations and focus on growth in obesity and diabetes treatments. The restructuring aims to save $1.25 billion by 2026, amid increasing competition in the obesity drug market.
Sep 10, 2025
Novo Nordisk lays off 9,000 employees to combat competition in the weight-loss medication market.
Novo Nordisk, the maker of Wegovy, announced it will cut 9,000 jobs, marking Denmark's largest layoffs, to save 8 billion Danish crowns annually amid slowing sales and competition from Eli Lilly's Zepbound. The restructuring aims to refocus on growth in diabetes and obesity markets under new CEO Mike Doustdar, as the company faces significant market cap losses.
Sep 10, 2025
Mike Tyson reveals his experience with fentanyl as he gears up for a major fight against Floyd...
Mike Tyson revealed on The Katie Miller Podcast that he used fentanyl multiple times during his boxing career in the 1990s, describing it as a powerful painkiller similar to heroin. He acknowledged his struggles with substance abuse and has since become an advocate for marijuana reform, promoting its benefits for pain management.
Sep 10, 2025
WHO supports the use of weight-loss medications | The Express Tribune
The World Health Organization has recommended GLP-1 agonists, including Ozempic, Wegovy, and Mounjaro, as essential medicines for treating diabetes and obesity. The WHO urges the production of affordable generic versions for developing countries, addressing the high mortality rates linked to obesity. Semaglutide and tirzepatide, the active ingredients in these drugs, were specifically highlighted in the announcement.
Sep 10, 2025
Novo Nordisk Reveals Significant Layoffs in Response to Intense Market Rivalry - Sri Lanka Guardian
Novo Nordisk plans to cut 9,000 jobs, or 11% of its workforce, amid rising competition from Eli Lilly in the weight-loss drug market. The company, known for Ozempic and Wegovy, revised its profit forecast and aims to save DKr8 billion annually by 2026. CEO Mike Doustdar emphasized the need for a cultural shift to enhance performance.
Sep 10, 2025
Novo Nordisk, the manufacturer of Wegovy, plans to cut 9,000 positions amid rising competition.
Novo Nordisk, the maker of Wegovy, announced it will cut 9,000 jobs, marking Denmark's largest layoffs, to save 8 billion Danish crowns annually amid fierce competition from Eli Lilly's Zepbound. The restructuring aims to revive growth after a significant drop in market value and sales stagnation. CEO Mike Doustdar plans to reinvest savings into drug development and market expansion.
Sep 10, 2025
Sanofi's Tzield and the Growing Type 1 Diabetes Treatment Market in China - AInvest
Sanofi's Tzield (teplizumab) has been approved in China as the first disease-modifying therapy for stage 2 type 1 diabetes (T1D) in patients aged eight and older. This approval marks a significant shift in T1D management, addressing unmet needs by preserving pancreatic beta-cell function. Tzield's entry into the Chinese market aligns with rising diabetes rates and government initiatives for innovative therapies.
Sep 10, 2025
Ssenfuka praises Museveni's backing: Is a cure for cancer and diabetes possible in Uganda? - The Observer
David Ssenfuka, a controversial herbalist in Uganda, received government support from President Yoweri Museveni to advance his herbal remedies for diabetes (SD2018) and cancer (CT) through clinical trials. With promising animal study results, Ssenfuka aims to transform these treatments into recognized medicines, emphasizing Uganda's potential for innovative healthcare solutions.
Sep 10, 2025
Novo Nordisk's Bold Reorganization: A Tactical Shift or an Indicator of Downturn? - AInvest
Novo Nordisk is cutting 9,000 jobs, 11% of its workforce, as it faces intensified competition from Eli Lilly, which dominates the obesity market with its drugs Zepbound and Mounjaro. Novo's restructuring aims to save $1.25 billion annually by 2026, following disappointing results from its CagriSema drug and a downward revision of its profit forecast for 2025.
Sep 10, 2025
FDA Awards Breakthrough Therapy Status to Eli Lilly's Olomorasib in Combination with ...
The FDA has granted Breakthrough Therapy Designation to Eli Lilly’s olomorasib in combination with Keytruda (pembrolizumab) for the first-line treatment of unresectable advanced non-small cell lung cancer (NSCLC). This designation aims to expedite the development of therapies that show significant improvement over existing treatments for serious conditions. Further studies will assess the efficacy and safety of this combination.
Sep 9, 2025
Novo Nordisk vs. Mylan: Treatment Method Claims Need to Correspond with Labeling - Lexology
The District of Delaware ruled against Novo Nordisk in its patent dispute with Mylan over Wegovy® (semaglutide). The court found that Mylan's label did not instruct avoidance of other therapeutic agents, undermining Novo's method-of-treatment claims. This case highlights the importance of aligning patent claims with FDA-approved labels and the challenges of proving inducement in ANDA cases.
Sep 9, 2025
On the 9th, GI Innovation revealed that it has secured a patent for its immuno-cancer formulation.
GI Innovation announced the registration of a patent for its immuno-cancer drug GI-101A in Europe, enhancing drug stability and delivery efficiency for both intravenous and subcutaneous injections. Currently entering phase 2 trials, GI-101A has shown strong anticancer activity in combination with Keytruda. The company aims to attract European investors following this patent and recent successes with GI-102.
Sep 9, 2025
DCGI reports that 97% of CDSCO's operations have transitioned to digital formats, according to DrugsControl Media Services.
The Drugs Controller General of India, Dr. Rajeev Singh Raghuvanshi, announced that 97% of operations at the Central Drugs Standard Control Organisation (CDSCO) are now digital, resulting in a 25% reduction in inefficiencies. This digital transformation aims to enhance regulatory processes in the pharmaceutical sector.
Sep 9, 2025
Hamlet BioPharma obtains additional patents to transform scientific findings into pharmaceuticals for the...
Hamlet BioPharma has secured five new patents in Australia, China, India, Japan, and the US, enhancing its intellectual property portfolio for its HAMLET drug candidates targeting cancer and infections. Notably, US Patent No. 12,331,073 introduces a novel manufacturing method for HAMLET drugs. The company now holds over 140 active patents, aiming to advance its innovative treatments through clinical trials.
Sep 9, 2025
WHO advocates for the global adoption of weight-loss medications and calls for the availability of affordable generic options.
The World Health Organization has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, for global diabetes and obesity treatment. The WHO urged affordable generics for developing countries, highlighting the high costs of these medications. Semaglutide was added to the essential medicines list, with potential for generic production at significantly lower prices.
Sep 9, 2025
Hamlet BioPharma obtains additional patents to transform scientific innovations into pharmaceuticals... - TradingView
Hamlet BioPharma has secured five new patents in Australia, China, India, Japan, and the US, enhancing its intellectual property portfolio. These patents focus on the HAMLET drug candidates, which target cancer cells and infections. The company now holds over 140 active patents and plans to integrate these technologies into future clinical trials, reaffirming its commitment to innovation in cancer treatment.
Sep 9, 2025
Immunic Expands Patent Portfolio: A Strategic Advantage in Treating Progressive MS - AInvest
Immunic has secured a pivotal U.S. patent for specific dose strengths of vidofludimus calcium, aimed at treating progressive multiple sclerosis (PMS), extending market exclusivity until 2041. This strategic move, combined with promising Phase 2 clinical data, positions Immunic favorably in the MS therapeutics market, enhancing its potential for growth and investor appeal.
Sep 9, 2025
Safeguarding intellectual property rights in the pharmaceutical sector has become more challenging.
GLP-1 drugs, including Ozempic, are transforming the pharmaceutical industry, with rising demand for weight management. Eli Lilly and Novo Nordisk, holding multiple patents, face challenges from generic producers and potential legislation like the Ethic Act S.2276, which could hinder their patent protections. As competition intensifies, the firms must navigate complex legal landscapes to maintain their market position.
Sep 9, 2025
$58 Billion Weight Loss Medication Market Expands: Exploring Cardiovascular Therapeutics
The global weight loss drug market has reached $58 billion, driven by GLP-1 medications like Novo Nordisk's Ozempic and Eli Lilly's Mounjaro. These drugs not only aid weight loss but also show promise in reducing heart disease risk and potentially slowing neurodegenerative diseases like Alzheimer’s and Parkinson’s. Their evolving role highlights a shift in treating obesity as a medical issue.
Sep 9, 2025
WHO Supports Weight-Loss Medications and Calls for Affordable Generic Options
The World Health Organization has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for diabetes and obesity. The WHO urges the production of affordable generics to ensure access in developing countries, where obesity-related deaths are high. The patent for semaglutide may expire soon, potentially lowering costs.
Sep 9, 2025
Dianthus Therapeutics (DNTH) Reaches Record Levels Following Positive Drug Trial Results - Yahoo Finance
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) reached a record high of $32.8 following positive results from its clinical trial of Claseprubart for generalized Myasthenia Gravis, showing significant improvements in patients. The company also announced a $150 million public offering to support further development. Investors are optimistic about Claseprubart's potential as a leading treatment for autoimmune disorders.
Sep 9, 2025
Dianthus Therapeutics (DNTH) Reaches Record Levels Following Positive Drug Trial Results
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) reached a record high of $32.8 following positive results from its clinical trial of Claseprubart for generalized Myasthenia Gravis (gMG). The trial showed significant improvements with no serious adverse events reported. Additionally, the company announced a $150 million public offering to support further development.
Sep 9, 2025
Could LLY's Oncology Portfolio Offer Significant Diversification Advantages? - The Globe and Mail
Eli Lilly's revenue surged 58% to $20.6 billion in the first half of 2025, driven by GLP-1 drugs Mounjaro and Zepbound. The oncology segment, led by Verzenio, contributed $4.4 billion. Lilly is advancing Jaypirca for earlier therapy lines and has promising data for imlunestrant in breast cancer. Despite a 4.5% stock decline, earnings estimates for 2025 have improved.
Sep 9, 2025
Elanco's CEO attributes the company's growth to successful blockbuster medications - AInvest
Elanco Animal Health (NYSE: ELAN) reports strong growth driven by high consumer spending on pet health and innovative drugs, as highlighted by CEO Jeff Simmons at the Morgan Stanley Conference. The company aims for 5-6% top-line growth in 2025, with a focus on products like Credelio Quattro and the upcoming IL-31 monoclonal antibody, enhancing its market position.
Sep 9, 2025
Patenting Established Medications for Specific Uses in Precision Medicine at the EPO (Video)
HGF, a leading intellectual property firm in Europe, discusses the patentability of known drugs when targeting specific patient sub-groups based on biomarkers. This approach, which distinguishes responders from non-responders, is supported by key case law under the European Patent Convention, potentially allowing for new patent protections in the pharmaceutical industry.
Sep 9, 2025
NRG Therapeutics Raises $67 Million to Progress Drug Development for Parkinson's and ALS
NRG Therapeutics has raised $67 million in Series B funding to advance its drug development for Parkinson’s disease and ALS, with investments from Merck KGaA and Novartis. The funds will support preclinical research and prepare for clinical trials of its investigational medicine targeting mitochondrial dysfunction, specifically inhibiting the mitochondrial permeability transition pore (mPTP).
Sep 9, 2025
GLP-1 Receptor Agonists such as Semaglutide and Liraglutide Become Increasingly Favored for Weight Management
GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda), are gaining popularity for weight loss, originally designed for type 2 diabetes. Their effectiveness in appetite regulation has led to increased demand, raising concerns about supply shortages and long-term safety. The medical community is discussing the implications of their widespread use for public health.
Sep 9, 2025
Elanco's CEO Claims Major Medications are Fueling Company Growth - Yahoo Finance
Elanco CEO Jeff Simmons reports that pet owners' willingness to spend is at an all-time high, fueling growth in innovative drugs for the company. This trend is seen as a significant tailwind for the pet pharmaceutical industry.
Sep 8, 2025
Increased demand for diabetes medication used for weight loss results in shortages, according to Lancet.
High demand for semaglutide, a diabetes medication now popular for weight loss, has led to shortages for patients needing it for blood sugar management, according to a Lancet article. Eli Lilly's Mounjaro and Novo Nordisk's Wegovy are now available in India, but their high costs, exceeding ₹15,000 monthly, pose accessibility challenges, especially in low-income regions.
Sep 8, 2025
Dermatologist advises to cease the use of fairness creams right away, as they may lead to increased facial hair growth.
Dr. Aanchal Panth, a dermatologist, has warned against the use of fairness creams, stating they can lead to increased facial hair and redness of the skin. She emphasized the dangers of these products in a recent Instagram post, highlighting that they can thin the skin and make veins more visible.
Sep 8, 2025
AAM: Escalating issues with ongoing patent lawsuits - Drug Store News
The Association for Accessible Medicines (AAM) and the Biosimilars Council released a white paper addressing serial patent litigation by brand drug manufacturers that delays access to affordable generic and biosimilar medications. AAM's CEO, John Murphy III, urged Congress to streamline patent litigation to enhance patient access and savings. The paper includes 10 case studies highlighting affected medications.
Sep 8, 2025
Research Discovers Protein Fragment Associated with Alzheimer's That Interferes with HIV-1 Assembly in Neural Cells
A study by Northwestern Medicine published in the *Proceedings of the National Academy of Sciences* has identified a protein fragment linked to Alzheimer’s disease that disrupts HIV-1 assembly in brain cells. This finding suggests a molecular connection between Alzheimer’s and HIV-1, offering new insights into the interactions between these two conditions.
Sep 8, 2025
Will the FDA's approved list put an end to unlawful GLP-1 compounding? - TechTarget
The FDA has introduced a "green list" import alert to prevent unverified GLP-1 active ingredients from entering the U.S., amid concerns over illegal compounded versions of GLP-1 drugs for weight loss. The agency aims to secure the drug supply chain, but experts question the effectiveness of this strategy in addressing regulatory neglect and enforcement gaps in compounding practices.
Sep 8, 2025
J&J and AbbVie: Which Healthcare Leader Comes Out on Top? - AInvest
Johnson & Johnson (JNJ) and AbbVie (ABBV) are both major players in healthcare, facing challenges from the patent cliff. JNJ's diversified portfolio and growth in its Innovative Medicine segment make it a more attractive investment compared to ABBV, which relies heavily on Humira and Skyrizi. JNJ's resilience and revenue from medical devices further enhance its investment appeal.
Sep 8, 2025
Korea accelerates biopharmaceutical initiatives aiming for a top-five global position by 2030.
The South Korean government is intensifying efforts to elevate its biopharma industry into the world's top five, as announced at the "Bio Innovation Forum." The "K-Bio Pharmaceutical Industry Leap Forward Strategy" aims to double exports, create three blockbuster drugs, and become the third-largest in clinical trials by 2030, leveraging AI and regulatory reforms to enhance innovation and competitiveness.
Sep 8, 2025
Is Johnson & Johnson a Dividend Powerhouse or a Gradual Pharma Performer? - AInvest
Johnson & Johnson (JNJ) maintains a 63-year streak of annual dividend increases, supported by a 53.34% payout ratio and $19.84 billion in free cash flow. However, the company faces challenges from the 2025 patent expiration of its drug Stelara, projected to cause a $2 billion revenue shortfall. JNJ's diversification and innovation strategies are crucial for sustaining its dividend amid these pressures.
Sep 8, 2025
Regeneron and Bayer's attempt to prevent Sandoz from introducing an Eylea biosimilar has been unsuccessful | Lawyerly
Regeneron and Bayer have failed in their attempt to prevent Sandoz from launching a biosimilar of their popular eye medication, Eylea. This decision marks a significant development in the ongoing competition within the pharmaceutical industry.
Sep 8, 2025
Exploring Bayer's Elinzanetant and the Transformation of Menopause Treatments: An In-Depth Analysis of Non...
Bayer's elinzanetant, a first-in-class dual NK-1 and NK-3 receptor antagonist, is poised to transform the menopause therapeutics market, addressing vasomotor symptoms like hot flashes. With promising Phase III trial results and approvals in the UK and Canada, it could capture significant market share, especially with a projected $741 million annual revenue opportunity in the U.S. by 2034.
Sep 8, 2025
WHO supports weight-loss medications and calls for affordable generic options - Pharmacy Business
The World Health Organization has recommended GLP-1 agonists, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro, as essential medicines for treating diabetes and obesity. The WHO urges the production of affordable generics to ensure access in developing countries, where obesity-related deaths are significant. The patent for semaglutide may expire soon, potentially lowering costs.
Sep 8, 2025
Regeneron's Strategic Role in the Biotech Sector Following Presentation - AInvest
Regeneron Pharmaceuticals showcased its robust R&D pipeline at the Morgan Stanley Global Healthcare Conference, aiming to deliver over 10 blockbuster drugs across oncology and immunology. Key products include DUPIXENT, generating $4.34 billion in Q2 2025, and Libtayo. Despite challenges with EYLEA's sales decline, Regeneron remains financially strong, investing $7 billion in R&D and manufacturing to sustain growth.
Sep 7, 2025
CVS Caremark is being sued in a class-action lawsuit regarding its coverage of Zepbound and Wegovy.
CVS Caremark is facing a class-action lawsuit for stopping coverage of Zepbound, Eli Lilly’s weight-loss drug, affecting around 200,000 patients. The lawsuit claims this decision violates federal law, as Zepbound is deemed more effective than Wegovy, a similar drug made by Novo Nordisk, which CVS now covers. CVS maintains the lawsuit is "without merit.
Sep 7, 2025
WHO includes GLP-1 medications such as Ozempic in its essential medicines list - Roya News
The WHO has updated its essential medicines list, adding key drugs like Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro for diabetes, Vertex Pharmaceuticals’ Trikafta for cystic fibrosis, and Merck’s Keytruda for various cancers. This move aims to enhance global access to these high-cost treatments, addressing critical health challenges like diabetes and obesity affecting over 1.8 billion people worldwide.
Sep 7, 2025
Could Pfizer Create Millionaires? - AOL.com
Pfizer's stock has plummeted nearly 60% from its 2022 peak, primarily due to overinflated expectations following its COVID-19 vaccine success. Despite facing patent cliffs and a temporary revenue boost, analysts suggest it remains a solid long-term investment. Pfizer offers a 6.8% dividend yield, but investors may want to consider alternatives like Merck and Bristol Myers Squibb for more reliable dividends.
Sep 7, 2025
SprintRay Purchases EnvisionTEC's Dental Product Line Along with Associated Patents and Trademarks
SprintRay has acquired EnvisionTEC’s dental product portfolio, including patents, trademarks, and inventory, to enhance its 3D printing capabilities in dentistry. This acquisition grants SprintRay access to proprietary technologies and materials from EnvisionTEC, formerly known as Desktop Health. Financial terms of the deal were not disclosed.
Sep 7, 2025
Biotech Shares Increase Following ACIP's Recommendations for RSV Vaccine and Gilead's Latest Updates...
Biotech stocks surged yesterday, with the XBI index showing significant gains, driven by the Advisory Committee on Immunization Practices (ACIP) issuing recommendations for RSV vaccines. Gilead Sciences also updated its pipeline projects, enhancing investor confidence in the sector. These developments are expected to positively impact vaccine adoption rates and market dynamics for companies involved in RSV research.
Sep 7, 2025
Implications for Investment in GLP-1 Medications Following WHO's Inclusion in Essential Medicines List
The WHO has added GLP-1 receptor agonists, including semaglutide (Novo Nordisk’s Ozempic) and tirzepatide (Eli Lilly’s Mounjaro), to its Essential Medicines List, aiming to improve access for diabetes and obesity treatment. This move could reshape market dynamics and pricing strategies for both companies, while also encouraging generic production as patents expire.
Sep 7, 2025
Summit Therapeutics encounters potential setback with lung cancer medication anticipated to be a major success.
Summit Therapeutics faces challenges with its lung cancer drug ivonescimab, as a study revealed that patients in North America and Europe experienced faster tumor progression compared to those in China. While the risk of progression decreased by 45% for Chinese patients, it only reduced by 33% for Western participants, failing to achieve statistical significance, complicating approval efforts in the U.S. and Europe.
